Daratumumab, an IgG1-kappa monoclonal antibody targeting CD38, has become a pillar of multiple myeloma treatment, both in the newly diagnosed [1,2] and relapsed/refractory settings [3]. This evidence concerns the gene CD38 and plasma cell myeloma.